Volume 17, Number 7—July 2011
High Incidence of Guillain-Barré Syndrome in Children, Bangladesh
To the Editor: Bangladesh has achieved remarkable success in its drive to eliminate poliomyelitis; no case has been reported from that country since 2000. Still, the nonpolio incidence rate of acute flaccid paralysis (AFP) in Bangladesh is 3.25 cases per 100,000 children <15 years of age (1). Guillain–Barré syndrome (GBS), an acute polyradiculoneuropathy, is the most frequent cause of AFP (2). GBS in Bangladesh is frequently preceded by an enteric infection caused by Campylobacter jejuni (3). Frequent exposure to enteric pathogens at an early age may increase the incidence of GBS. We hypothesized that most AFP cases in Bangladesh can be diagnosed as GBS. Our objective was to estimate the crude incidence rate of GBS among children <15 years of age in Bangladesh.
In collaboration with the World Health Organization (WHO), the Government of Bangladesh conducts active AFP surveillance. AFP is defined as acute onset of focal or general flaccid (hypotonic) weakness without other obvious cause (e.g., trauma) in children <15 years of age. Data on the number of reported AFP cases in Bangladesh during 2006 and 2007 were obtained. On the basis of clinical and other information routinely collected through the surveillance system, we defined a GBS case as presence of an acute flaccid (hypotonic) paralysis and symmetrical weakness (4) in the absence of injury or birth trauma.
Bangladesh is divided into 6 divisions (major administrative regions) comprising 64 districts. Crude incidence data for GBS were calculated per division and per district on the basis of the population <15 years of age reported by WHO and the Government of Bangladesh.
In 2006 and 2007, a total of 1,619 and 1,844 AFP cases, respectively, were reported in children <15 years of age, of which 608 (37%) and 855 (46%) cases, respectively, fulfilled the GBS case definition. The crude incidence rate for GBS in children <15 years of age varied from 1.5 to 1.7 cases per 100,000 population in the 3 northern divisions (Dhaka, Rajshahi, and Sylhet) and from 2.1 to 2.5 per 100,000 in the 3 southern divisions (Khulna, Barisal, and Chittagong) (Figure A1). Overall, the crude incidence rate of GBS in children <15 years of age varied from 1.5 to 2.5 cases per 100,000 population per year in the 6 divisions of Bangladesh. Incidence rates were high (>5.0/100,000) in the Meherpur and Barisal districts in southern Bangladesh. We found a seasonal fluctuation in the frequency of patients with GBS; the most cases occurred in May (n = 159) and the lowest in February (n = 84). GBS occurred predominantly among boys (59%).
Most incidence studies reported in the literature originate from Europe and North America (5). A recent review reported that the best estimate of the global incidence of GBS in children <15 years of age is 0.6 cases per 100,000 population per year (5). Reports on incidence rates in developing countries are scarce. The crude incidence rate of GBS in Bangladesh in children <15 years of age reported here appears to be 2.5× to 4× higher than that reported in the literature. A statistically significant proportion of AFP cases in Bangladesh appear to be caused by GBS. We cannot explain the difference in incidence rates of GBS in the 3 northern divisions and the 3 coastal divisions in southern Bangladesh, in which rates are higher. However, differences in incidence rates between northern and southern Bangladesh may be explained by difference in climate or epidemiology. Further research is required to determine why GBS would occur more frequently in southern Bangladesh. Population-based data correlate well with a smaller scale hospital-based study in Khulna (6), in which GBS was diagnosed in 47% of hospitalized AFP case-patients. Our recent hospital-based study shows that 25% of GBS case-patients in Bangladesh are children <15 years of age (3). It is important to highlight that the present population-based analysis is based on a simplified case definition for GBS. All 25 children in the hospital study in whom GBS was diagnosed on the basis of National Institute of Neurological Disorders criteria (7) were also detected through population-based surveillance and fulfilled the simplified GBS case definition. Future studies, however, should include a validation of the case definition used here.
The possibility that GBS is related to pandemic (H1N1) 2009 and the affiliated vaccination campaign has resurfaced recently (8). For successful surveillance of excess GBS cases after pandemic (H1N1) 2009 and for postmarketing surveillance of the safety of new vaccines in general, data on the background incidence of GBS are critical. This report indicates that the effect of GBS in Bangladesh is substantial and suggests that data obtained through the ongoing global AFP surveillance program can be used to obtain crude incidence data on GBS worldwide.
We thank Tazul Islam and S.P. Luby for support and discussions with WHO and Alex van Belkum for critical review of the manuscript. We acknowledge with gratitude the commitment of the Government of Bangladesh to the research efforts of the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B).
This research was funded by ICDDR,B and the Government of Bangladesh through Improved Health for the Poor: Health Nutrition and Population Research Project. The following donors provide unrestricted support to ICDDR,B research efforts: Australian Agency for International Development, Government of the People’s Republic of Bangladesh, Canadian International Development Agency, Embassy of the Kingdom of the Netherlands, Swedish International Development Cooperation Agency, Swiss Agency for Development and Cooperation, and Department for International Development, UK.
- World Health Organization. EPI surveillance bulletin, vol. 11, no. 6. 2008 [cited 2010 Dec 1]. http://www.searo.who.int/vaccine
- van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7:939–50.
- Islam Z, Jacobs BC, van Belkum A, Mohammad QD, Islam MB, Herbrink P, Endemic axonal variant of Guillain-Barré syndrome frequently associated with Campylobacter infections in Bangladesh. Neurology. 2010;74:581–7.
- Landaverde JM, Danovaro-Holliday MC, Trumbo SP, Pacis-Tirso CL, Ruiz-Matus C. Guillain-Barré syndrome in children aged <15 years in Latin America and the Caribbean: baseline rates in the context of the influenza A (H1N1) pandemic. [PMID: 20102270]. J Infect Dis. 2010;201:746–50.
- McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide: a systematic literature review. Neuroepidemiology. 2009;32:150–63.
- Rasul CH, Das PL, Alam S, Ahmed S, Ahmed M. Clinical profile of acute flaccid paralysis. Med J Malaysia. 2002;57:61–5.
- Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27:S21–4.
- Evans D, Cauchemez S, Hayden FG. Prepandemic immunization for novel influenza viruses, “swine flu” vaccine, Guillain-Barré syndrome, and the detection of rare severe adverse events. J Infect Dis. 2009;200:321–8.
- Figure A1. Crude incidence rate (per 100,000 population/year) of Guillain-Barré syndrome in children <15 years of age, Bangladesh, 2006 and 2007.
Suggested citation for this article: Islam Z, Jacobs BC, Islam MB, Mohammad QD, Diorditsa S, Endtz HP. High incidence of Guillain-Barré syndrome in children, Bangladesh [letter]. Emerg Infect Dis [serial on the Internet]. 2011 Jul [date cited]. http://dx.doi.org/10.3201/eid1707.101999
Please use the form below to submit correspondence to the authors or contact them at the following address:
Address for correspondence: Zhahirul Islam, Enteric and Food Microbiology Laboratory, Laboratory Sciences Division, International Centre for Diarrheal Diseases Research, Mohakali, Dhaka-1212, Bangladesh
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: August 18, 2011
- Page last updated: August 18, 2011
- Page last reviewed: August 18, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)